Cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia: clinical characteristics, temporal relationships, and survival data in a series of 14 patients at Mayo Clinic

2013 ◽  
Vol 53 (8) ◽  
pp. 966-970 ◽  
Author(s):  
Michael B. Chang ◽  
Amy L. Weaver ◽  
Jerry D. Brewer
Keyword(s):  
T Cell ◽  
Chronic Lymphocytic Leukemia ◽  
Survival Data ◽  
Mayo Clinic ◽  
Clinical Characteristics ◽  
Cell Lymphoma ◽  
Lymphocytic Leukemia ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Temporal Relationships

scholarly journals Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma

2017 ◽  
Vol 56 (11) ◽  
pp. 1125-1129 ◽  
Author(s):  
Timothy W. Chang ◽  
Amy L. Weaver ◽  
Tait D. Shanafelt ◽  
Thomas M. Habermann ◽  
Cooper C. Wriston ◽  
...  
Keyword(s):  
T Cell ◽  
Chronic Lymphocytic Leukemia ◽  
Hodgkin Lymphoma ◽  
Cell Lymphoma ◽  
Lymphocytic Leukemia ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Non Hodgkin Lymphoma

scholarly journals Coincidence of B-cell chronic lymphocytic leukemia and cutaneous T-cell lymphoma (mycosis fungoides): immunologic characterization by monoclonal antibodies

Blood ◽  
1983 ◽  
Vol 62 (6) ◽  
pp. 1176-1181 ◽  
Author(s):  
K Sheibani ◽  
SJ Forman ◽  
CD Winberg ◽  
H Rappaport
Keyword(s):  
T Cell ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Cell Lymphoma ◽  
Lymphoproliferative Disease ◽  
Lymphocytic Leukemia ◽  
Lymphoid Cells ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Cell Type

Abstract Although rare cases of chronic lymphocytic leukemia (CLL) of the T-cell type have been reported, CLL is more commonly found to be a neoplastic lymphoproliferative disease of B-cell origin. In this article, we describe a patient with long-standing CLL that was immunologically shown to be of the B-cell type, who, during the course of his disease, developed cutaneous T-cell lymphoma (CTCL), which was shown to be of the helper/inducer subtype. The neoplastic lymphoid cells in the skin infiltrate differed morphologically and immunologically from those in the peripheral blood. The occurrence of CTCL during this patient's clinical course represents a second neoplasm arising from a different cell line, rather than a tissue manifestation of the patient's CLL. To our knowledge, this is the first report in which the occurrence of CTCL is documented in a patient with immunologically known B-cell CLL. In addition to establishing the presence of B-cell CLL and CTCL of the helper/inducer T-cell type in the same patient, this case report demonstrates the usefulness and necessity of evaluating lymphoproliferative disorders by means of a multidisciplinary approach.

Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody.

1984 ◽  
Vol 2 (8) ◽  
pp. 881-891 ◽  
Author(s):  
R O Dillman ◽  
D L Shawler ◽  
J B Dillman ◽  
I Royston
Keyword(s):  
Monoclonal Antibody ◽  
T Cell ◽  
Chronic Lymphocytic Leukemia ◽  
Cell Lymphoma ◽  
Lymphocytic Leukemia ◽  
T Cell Lymphoma ◽  
Target Cells ◽  
Cutaneous T Cell Lymphoma ◽  
Clinical Value ◽  
Human T Cell

The findings accompanying the administration of 50 intravenous courses of monoclonal antibody to human T-cell (T101) in eight patients, four with chronic lymphocytic leukemia and four with cutaneous T-cell lymphoma are reported. Infusion rates of 0.7 to 1 mg/min were associated with unacceptable toxicity in the presence of circulating target cells, but slower rates were well-tolerated. Immunofluorescence techniques confirmed that circulating cells did bind the antibody in vivo and were subsequently removed from the circulation. Modulation of the antigen on target cells in the bone marrow and skin has important implications for the schedule of administration of such antibodies, and points out the possible limitation of effector cell-mediated cytotoxicity at the tissue level. Production of anti-mouse antibodies resulted in neutralization of therapy in two patients with cutaneous T-cell lymphoma, and suggests that whether such an anti-mouse response is produced may be secondary to the underlying immune status of the patient or the amount of mouse protein to which immunocompetent cells are exposed. The relative specificity and efficacy of monoclonal antibody therapy is encouraging, but the limited clinical benefit and problems of modulation and anti-mouse antibody production underscore the need for continued research into passive therapy and suggest that cytotoxic conjugates may be of more clinical value.

scholarly journals Coincidence of B-cell chronic lymphocytic leukemia and cutaneous T-cell lymphoma (mycosis fungoides): immunologic characterization by monoclonal antibodies

Blood ◽  
1983 ◽  
Vol 62 (6) ◽  
pp. 1176-1181
Author(s):  
K Sheibani ◽  
SJ Forman ◽  
CD Winberg ◽  
H Rappaport
Keyword(s):  
T Cell ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Cell Lymphoma ◽  
Lymphoproliferative Disease ◽  
Lymphocytic Leukemia ◽  
Lymphoid Cells ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Cell Type

Although rare cases of chronic lymphocytic leukemia (CLL) of the T-cell type have been reported, CLL is more commonly found to be a neoplastic lymphoproliferative disease of B-cell origin. In this article, we describe a patient with long-standing CLL that was immunologically shown to be of the B-cell type, who, during the course of his disease, developed cutaneous T-cell lymphoma (CTCL), which was shown to be of the helper/inducer subtype. The neoplastic lymphoid cells in the skin infiltrate differed morphologically and immunologically from those in the peripheral blood. The occurrence of CTCL during this patient's clinical course represents a second neoplasm arising from a different cell line, rather than a tissue manifestation of the patient's CLL. To our knowledge, this is the first report in which the occurrence of CTCL is documented in a patient with immunologically known B-cell CLL. In addition to establishing the presence of B-cell CLL and CTCL of the helper/inducer T-cell type in the same patient, this case report demonstrates the usefulness and necessity of evaluating lymphoproliferative disorders by means of a multidisciplinary approach.

Sign in / Sign up

Export Citation Format

Share Document